AZD8186

Known as: AZD-8186, PI3Kbeta Inhibitor AZD8186 
An inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. Upon administration, PI3Kbeta inhibitor… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
012320152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Purpose: PTEN-null tumors become dependent on the PI3Kβ isoform and can be targeted by molecules such as the selective PI3K… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Purpose: PTEN-null tumors become dependent on the PI3Kb isoform and can be targeted by molecules such as the selective PI3Kb… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
BACKGROUND The phosphatidylinositol 3 kinase (PI3K) signalling pathway is frequently altered in human cancer and a promising… (More)
Is this relevant?
2016
2016
Selective phosphoinositide 3-kinase (PI3K)/AKT/mTOR inhibitors are currently under evaluation in clinical studies. To identify… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
Loss of PTEN protein results in upregulation of the PI3K/AKT pathway, which appears dependent on the PI3Kβ isoform. Inhibitors of… (More)
  • table 1
Is this relevant?
2015
2015
Several studies have highlighted the dependency of PTEN deficient tumors to PI3Kβ activity and specific inhibition of PI3Kδ has… (More)
Is this relevant?
2015
2015
BACKGROUND The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT pathway is frequently activated during prostate cancer… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?